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Abstract
Background: Infection-related exacerbations of respiratory diseases are a major health concern; thus understanding the
mechanisms driving them is of paramount importance. Despite distinct inflammatory profiles and pathological differences,
asthma and COPD share a common clinical facet: raised airway ATP levels. Furthermore, evidence is growing to suggest that
infective agents can cause the release of extracellular vesicle (EVs) in vitro and in bodily fluids. ATP can evoke the P2X7/
caspase 1 dependent release of IL-1b/IL-18 from EVs; these cytokines are associated with neutrophilia and are increased
during exacerbations. Thus we hypothesized that respiratory infections causes the release of EVs in the airway and that the
raised ATP levels, present in respiratory disease, triggers the release of IL-1b/IL-18, neutrophilia and subsequent disease
exacerbations.
Methods: To begin to test this hypothesis we utilised human cell-based assays, ex vivo murine BALF, in vivo pre-clinical
models and human samples to test this hypothesis.
Results: Data showed that in a murine model of COPD, known to have increased airway ATP levels, infective challenge
causes exacerbated inflammation. Using cell-based systems, murine models and samples collected from challenged healthy
subjects, we showed that infection can trigger the release of EVs. When exposed to ATP the EVs release IL-1b/IL-18 via a
P2X7/caspase-dependent mechanism. Furthermore ATP challenge can cause a P2X7 dependent increase in LPS-driven
neutrophilia.
Conclusions: This preliminary data suggests a possible mechanism for how infections could exacerbate respiratory diseases
and may highlight a possible signalling pathway for drug discovery efforts in this area.
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Introduction
Asthma and Chronic Obstructive Pulmonary Disease (COPD)
are respiratory diseases with ever-increasing global prevalence [1–
3] that represent a social and economic burden for industrialised
and developing countries [4]. The World Health Organization
currently states the number of patients suffering from asthma is
300 million and predicts this figure to rise to 400 million by 2025
[5], whereas there are 600 million COPD sufferers worldwide and
the disease is predicted to be the third ranked leading cause of
death by 2020 [5].
Exacerbations are common events in the lives of patients with
asthma and COPD [6–8]. These episodes are often associated
with infections by viruses or bacteria [9] and cause worsening of
symptoms, which can be fatal. Often these heightened symptoms
are far less responsive to normal treatments and are associated
with increased health care costs and societal impact [10]. Increases
in inflammatory status, particularly IL-1b and neutrophilia, in the
airway are evident during exacerbations of both diseases [9,11–
16]. Furthermore, there is increasing evidence to suggest that the
exacerbations accelerate the progressive decline in lung function
[8,11]. Therefore there is an urgent need to understand the
mechanisms driving exacerbations and identify novel therapeutic
interventions to target this cohort of patients.
Extracellular vesicles (EV) such as exosomes and microvesicles
have been shown to be released from a diverse range of cell types
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in response to infective agents/pathogens and are believed to
primarily function in immune surveillance and host defence
(recently reviewed [17–19]. These vesicles contain proteins, lipids,
mRNA and microRNA; they typically range from 30 nm to 1 mm
in size and are found in many biological fluids. Recent cell-based
studies have shown that ATP-stimulated EVs release IL-1b and
IL-18 via the P2X7/caspase-1 axis [20–23] and it is known that
these cytokines are involved in airway neutrophilia, activation of
macrophages and the maintenance of a chronic inflammatory
response [4]. Furthermore, it has been reported that ATP levels
are increased in the airways of patients with asthma and COPD
[24–27]. Indeed, despite distinct inflammatory and pathological
patterns, raised ATP levels in asthma and COPD represents one
common clinical attribute. Therefore our hypothesis is that
exacerbations of asthma and COPD during respiratory infections
are due to ATP (a known danger associated molecular pattern)
activating the P2X7/caspase-1 axis within EVs resulting in the
release of IL-1b and IL-18, and subsequently increasing neutro-
philia and worsening of symptoms that may accelerate disease
pathogenesis. Initial cell based data confirmed previous findings
that a bacterial mimetic can cause the release of EVs [23] and
indicated to us that we could use the ATP driven release of IL-1b
as a marker of the presence of EVs in our biological samples. We
then used Electron Microscopy (EM), Nanosight Technology and
pharmacology to show that inhaled endotoxin causes the release of
EVs in the airways of mice and man. Furthermore, parallel EV
release in the airway could be triggered with live bacteria and a
viral mimetic. Finally we showed that exogenous ATP can trigger
a P2X7 receptor dependent exacerbated response to inhaled
bacterial mimetic.
Materials and Methods
Demonstration that bacterial mimetic (LPS)-induced
release of EVs can enhance IL-1b and neutrophil levels
and change disease phenotype in model known to have
increased levels of ATP
To begin to investigate our hypothesis we first determined if we
could model the exacerbated inflammatory response to inhaled
infective agent. Recently, its been shown that inhaled bacterial
mimetic, LPS, causes greater inflammation if rats have been
exposed to cigarette smoke [22]. We, and others, have shown that
cigarette smoke causes an increase in airway ATP levels [21,23],
indeed it seems likely that the ATP, acting on P2X7 receptor, that
is driving the inflammation after exposure to cigarette smoke
[24,25]. Thus it is conceivable that the exacerbated neutrophilia
reported by Hardaker et al. [22] could be through the ATP-EV-
IL-1b axis. As much of the recent work performed by our group
and our collaborators is performed using mice, we first wanted to
repeat the study reported by Hardaker et al. (2010) in mice.
All animal procedures were approved by the British Home
Office, under the United Kingdom Animal (Scientific Procedures)
Act 1986 (Project license 70/7212). Male adult C57bl/6 mice (18–
25 gm) were purchased from Harlan UK Ltd and maintained in
cages under controlled temperatures (19–23uC) and lighting (12-h
Figure 1. Demonstration that LPS-induced release of EVs can enhance IL-1b and neutrophil levels and change disease phenotype in
model known to have increased levels of ATP. Mice (n = 8 per treatment group) were exposed to either room air (control) or CS (3R4F
cigarettes) using a negative pressure system. Mice were subjected to 2 periods of CS exposure (500 ml/minute) per day (4 hours apart) for 3
consecutive days. On the morning of the third challenge day, the mice were exposed to aerosolised vehicle of endotoxin free saline or LPS (1 mg/ml)
in Perspex chambers for 30 minutes. Animals were culled and BALF and lung tissue samples were collected 24 hours after LPS treatment. IL-1b levels
were measured in the BALF and neutrophil numbers were determined in the BALF and lung tissue. In separate BALF samples collected from parallel
smoke or LPS driven challenges ATP levels were measured (Panel A). Data shown as mean +/2 S.E.M. (A: ATP # =P= 0.0023, Mann-Whitney; B: IL-1b
# =P=0.0009, Mann-Whitney; C: BALF neutrophil number,# =P=0.0431, Students T test; D: lung tissue neutrophil number; # =P= 0.0006, Mann-
Whitney).
doi:10.1371/journal.pone.0101087.g001
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light, 12-h dark cycle, lights on at 07:00 hrs). All mice had ad
libitum access to water and chow (RM1 diet; Special Diet Services,
Devon, UK).
The protocol for this study was designed specifically to examine
the effect of the combination of the two stimuli. We focused not on
the optimum time for smoke induced inflammation but when we
knew the ATP levels were increased. Mice (n = 6 per treatment
group) were exposed to either room air (control) or CS (3R4F
cigarettes; Tobacco Health Research Institute, University of
Kentucky, Lexington, KY, USA) using a negative pressure system
as previously described [28,29]. Mice were subjected to 2 periods
of CS exposure (500 ml/minute) per day (4 hours apart) for 3
consecutive days. On the morning of the third day, the mice were
challenged with aerosolised vehicle of endotoxin-free saline
(Fresenius Kabi Ltd, Warrington, UK) or LPS (1 mg/ml; to
mimic bacterial infection) in Perspex chambers for 30 minutes (as
previously described, [28,30]. Animals were culled and BALF and
lung tissue samples were collected 24 hours after LPS treatment.
IL-1b levels were measured in the BALF and neutrophil numbers
determined in the BALF and lung tissue digest as described in
Birrell et al. and Eltom et al. [28,31].
BALF ATP levels were determined in samples from separate
parallel smoke and LPS driven studies using an ATPlite
luminescence assay.
Demonstration of the concept that an infective insult can
cause EV release
To confirm that it was appropriate to use ATP induced IL-1b as
a biological marker of functional EV presence we used a cell based
system [23]. THP-1 (Human acute monocytic leukemia cell line)
monocytes were obtained from the European Collection of Cell
Cultures (Wiltshire, UK), cultured in Roswell Park Memorial
Institute medium (RPMI) 1640 medium plus GlutaMAX-I and
supplemented with 10% foetal calf serum and 1% Penicillin/
Streptomycin/Amphotericin B. Cells were maintained under
sterile conditions in a humidified atmosphere of 37uC containing
95% air, 5% (v/v) CO2. Cells were cultured 10
6 per T-75 culture
flasks (Corning Inc, NY, USA). Trypan Blue exclusion was
performed to determine cell viability. Cells were then incubated
for one hour at 37uC in a humidified atmosphere (95% air; 5% (v/
v) CO2) in order to settle. Flasks were treated with RPMI (vehicle)
or LPS (0.1 mM, final concentration of Escherichia coli serotype
0111:B4 (Sigma-Aldrich Co)) and incubated overnight at 37uC
(95% air; 5% (v/v) CO2). Eighteen hours after treatment, samples
were collected and centrifuged at 900 g for 10 minutes to remove
the cells. The supernatants were collected and split into two equal
fractions. One fraction (EV-rich) was stored at 280uC without
further processing. The other fraction was ultracentrifuged at
100,0006g for 2 hours (4uC) to remove the EVs. The supernatant
(EV-deficient) was stored at 280uC for further experiments.
Supernatant samples from both fractions were thawed at room
Figure 2. Demonstration of the concept that a bacterial mimetic insult can cause EV release. THP-1 cells were treated with RPMI (vehicle)
or LPS (0.1 mM) and incubated overnight and samples were collected and centrifuged to remove the cells. The supernatants were collected and split into
two equal fractions: non-ultracentrifuged (EV-rich – left side) and ultracentrifuged (EV-deficient – right side). The samples were pre-treated with vehicle
(DMSO, 0.1%, V/V) or P2X7 antagonist (AZ 11645373; 10
27 M). Samples were incubated for one hour and then treated with vehicle (PBS) or
exogenous ATPcS (1023 M). The samples were then incubated for a further 4 hours prior to ELISA assessment for cytokines (A: IL-1b, B: IL-18, C: TNFa,
D: MMP-9). The data is shown as mean +/2 S.E.M.
doi:10.1371/journal.pone.0101087.g002
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temperature and 100 ml of each sample was pre-treated with
vehicle (DMSO, final concentration 0.1%, V/V) or P2X7
antagonist (AZ 11645373; 1027 M; AstraZeneca Pharmaceuticals
PLC (AZ), UK – concentration established in Eltom et al. 2011).
Samples were incubated for one hour (37uC; 95% air; 5% (v/v)
CO2) and then subsequently treated with RPMI (vehicle) or
Adenosine 59-[c-thio]triphosphate tetralithium salt (ATPcS; Sig-
ma-Aldrich Co; 1023 M – concentration established in Eltom et al.
2011). Thereafter, the samples were incubated for 4 hours (37uC;
95% air; 5% (v/v) CO2) prior to ELISA assessment for cytokines
linked to the P2X7-inflammasome axis, IL-1b and IL-18, and
control non-inflammasome markers such as TNFa and MMP-9.
ELISAs used were purchased from R&D Systems Europe Ltd,
Oxfordshire, UK.
Determining if a bacterial mimetic can cause the release
of EVs in the lung
Having demonstrated the concept that a bacterial mimetic
insult can cause the release of EVs and IL-1b is useful biological
marker of their presences, we then wanted to determine if a range
of infective mimics/agents would cause the release of EVs in the
airway. To do this we challenged mice with bacterial and viral
mimetics, collected the lavage fluid and examined ATP-induced
EV release of IL-1b (IL-18 was not measured in all experiments
because of the limited sample obtained and the cost of the assays).
Bacterial mimetic: LPS
Mice (n = 6 per group) were challenged with the aerosolised
vehicle or LPS as described above. Animals were sacrificed and
BALF samples were obtained 6 hours after challenge.
To assess the presence of EV’s in the BALF they were first
centrifuged (900 g) to remove the white blood cells and debris.
Samples were then:
Visualisation of extracellular vesicles by electron
microscopy
BALF was collected from a parallel set of mice described above,
the white cells and debris were removed by centrifugation (3000 g)
and then the EVs collected via ultracentrifugation (100,000 g). A
drop of the resuspended EVs was placed on Formvar carbon-
coated copper electron microscopy grids. Samples were subse-
quently fixed in 4% paraformaldehyde/1% gluteraldehyde in
phosphate buffer, washed 10 times with ddH2O, stained with 1%
methyl cellulose/2% uranyl acetate pH 4 on ice and visualised
with a JEOL 1010 Transmission Electron Microscope (Welwyn
Garden City, UK). Images were taken with a Gatan Orius
SC100B charge-coupled device camera.
Visualisation of extracellular vesicles by Nanosight
Technology
The Nanosight (Amsebury, UK) system has recently been
suggested to be the most appropriate way of assessing the size
profile of EVs in biological fluids [32,33]. It was used under the
guidance of one of their trained technicians and made possible
through a grant from The Rosetrees Trust, (A523).
Quantitating extracellular vesicles by measuring ATP
induced cytokine release
Samples were treated with RPMI (vehicle) or exogenous ATPcS
(Sigma-Aldrich; 1023 M, concentration established previous-
ly,[28]) and incubated for a further 4 hours (37uC; 95% air; 5%
(v/v) CO2). Samples were then collected and stored for cytokine
analysis by specific ELISA. Levels of IL-1b, IL-1a and IL-18 were
determined.
Assessing the role of P2X7 and caspase in the release of
IL-1b
Samples were pre-treated with inhibitors (P2X7 antagonist
A438079 (1026 M); Abbot Laboratories and caspase-1 inhibitor
VX-765 (1027 M); Vertex Pharmaceuticals, Oxfordshire, UK)
and incubated for 1 hour. For these experiments we used the
Figure 3. Determining if a bacterial mimetic (LPS) can cause the
release of EVs in the lung – Electron Microscopy. Mice were
challenged with the aerosolised vehicle of endotoxin-free saline or LPS
(1 mg/ml) in Perspex chambers for 30 minutes. Animals were sacrificed
and BALF obtained 6 hours after challenge. The samples were then
centrifuged (900 g) to remove the white blood cells and debris. The
presence of EVs was imaged using EM (top panel – vehicle, middle
panels – vehicle challenge, bottom panels – LPS challenge).
doi:10.1371/journal.pone.0101087.g003
Figure 4. Determining if a bacterial mimetic (LPS) can cause the
release of EVs in the lung – Nanosight imaging. Mice were
challenged with the aerosolised vehicle of endotoxin-free saline or LPS
(1 mg/ml) in Perspex chambers for 30 minutes. Animals were sacrificed
and BALF obtained 6 hours after challenge. The samples were then
centrifuged (900 g) to remove the white blood cells and debris. The
presence of EVs was imaged using Nanosight technology.
doi:10.1371/journal.pone.0101087.g004
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Abbott compound because we have previously found that, unlike
the AZ compound, it is effective antagonist of the murine P2X7
receptors [28]. Thereafter, RPMI (vehicle) or exogenous ATPcS
(Sigma-Aldrich; 1023 M) were added to the samples and
incubated for a further 4 hours (37uC; 95% air; 5% (v/v) CO2).
Samples were then collected and stored for cytokine analysis by
ELISA. TNFa was measured as a negative control.
LPS challenge in healthy subjects
To translate our murine findings we repeated some of the
assessment in BALF samples collected from healthy human
subjects challenged with vehicle (n = 5) or LPS (n = 10). Samples
were generated as described in a study by Shyamsundar [34].
Shyamsundar et al. reported that ‘‘The study was approved by the
local research ethics committee, and written informed consent was
obtained from all subjects before enrolment in the study’’. Briefly,
LPS (Escherichia coli serotype O26:B6) was dissolved in endotox-
in-free sterile 0.9% saline and inhaled via an automatic
inhalation–synchronized dosimeter nebulizer (Spira). The total
dose of inhaled LPS was 50 mg. Bronchoalveolar lavage (BAL)
was performed 6 hours after vehicle of LPS challenge. Cells were
removed via centrifugation (900 g) and the BALF supernatant
processed as described above.
BALF ATP levels were determined in samples from separate
parallel smoke and LPS driven studies using an ATPlite
luminescence assay.
Live bacterial challenge: H. influenzae
To show that live bacterial challenge causes the release of EVs,
mice were infected with Haemophilus influenzae (H. influenzae).
Briefly, Hib Eagan strain was a kind gift from P. Langford
(Faculty of Medicine, St Mary’s Hospital, Imperial College
London). Bacteria were cultured at 37uC in 5% CO2 in Brain
heart Infusion broth (OXOID) supplemented with 10 mg/ml of
both Hemin (10ug/ml) and Nictinamide adenine dinucleotide
(NAD) (Sigma-Aldrich, UK) or on BHI agar (OXOID) supple-
mented with 4% Levinthals when agar was ,50uC. Levinthals was
made by adding 50% horse blood (TCS Biosciences) to BHI broth
and heating to 70uC for 45 minutes. On cooling to 50uC, 0.7 mg/
ml NAD was added and the supernatant stored at –80uC. Bacteria
were cultured to an OD600 of 0.3 (approximately 16109 CFU/
ml) and stored at 280uC in 10% glycerol as single use aliquots.
Groups of mice (n = 4–5 per group) were infected i.n. with
16107 colony forming units of H. influenzae serotype b (strain
Eagan) in sterile phosphate buffered saline (PBS). Terminal
anaesthesia was induced at 6, 24 and 72 hours after challenge.
Mice were culled and BALF samples were collected at 6, 24 and
48 hours. Presence of EVs was assessed as detailed above.
Figure 5. Determining if a bacterial mimetic (LPS) can cause the release of EVs in the lung – Cytokine release. Mice were challenged
with the aerosolised vehicle of endotoxin-free saline or LPS (1 mg/ml) in Perspex chambers for 30 minutes. Animals were sacrificed and BALF
obtained 6 hours after challenge. The samples were centrifuged (900 g) to remove the white blood cells and debris, and then treated with vehicle
(PBS) or ATPcS (1023 M), and incubated for a further 4 hours and subsequent cytokine release was analysed by ELISA. Data shown as mean +/2 S.E.M.
(A: IL-1b, B: IL-18, C: IL-1a).
doi:10.1371/journal.pone.0101087.g005
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Viral mimetic: Poly IC
To determine if viral challenge would cause EV we challenged
mice with vehicle or the viral mimetic of Polyinosinic: polycytidylic
acid (Poly I:C) as previously described [35]. Briefly, mice (n = 6 per
group) were anesthetized with isoflurane (4% isoflurane in oxygen;
Abbot Laboratories, Maidenhead, UK) and were intranasally (i.n.)
administered with 50 ml (approximately 25 ml per nostril) of either
saline (vehicle) or a 0.6 mg/ml solution of Poly I:C (Invitrogen
Ltd, UK). Mice were culled and BALF samples were collected at 2,
6 and 24 hours. Presence of EVs was assessed as described above.
Determining whether the ATP/P2X7 axis is central to the
exacerbation response in vivo
Finally, experiments were performed to show that the ATP/
P2X7 axis can exacerbate responses to inhaled bacterial mimetic in
vivo. We were not able to use the smoke plus LPS exacerbation
model systems because we, and others, have shown that ATP and
P2X7 are central to the smoke only model, thus interpretation of
any agents designed to modulate ATP/P2X7 would be difficult
[27,28]. Previously, we have shown that the inflammation in the
basic LPS model is not modulated by a P2X7 inhibitor (22), thus it
was ideal to use as a mechanistic model for testing the hypothesis
that the P2X7 receptor was involved in the ATP-driven
exacerbation. Briefly, the mice were challenged with vehicle or
LPS, and four hours later intranasally dosed with saline (2 ml/kg)
or ATPcs (0.001 mg/kg, Sigma, UK) whilst under light anaes-
thesia (4% isoflurane in oxygen). The mice received oral vehicle or
P2X7 inhibitor, A438079 (1000 mg/kg), 30 minutes prior to the
ATP challenge, 4 hours after the challenge and 1 hour prior to
cull. Twenty Four hours after the LPS exposure the mice were
culled and lavaged. Neutrophils numbers were measured in the
BALF as described in Eltom et al. [28].
Data analysis
All data are expressed as mean +/2 standard error of mean
(S.E.M) of n observations. Experiments were statistically analysed
utilising the Students unpaired t-test for parametric data and the
Mann-Whitney U-test for non-parametric data with independent
groups compared with their specific controls or time-matched
controls. For multiple comparison tests, statistical analysis was
performed by applying One-way analysis of variance (ANOVA)
followed by a Bonferroni’s multiple comparison post-test for
parametric data or a Kruskal-Wallis test incorporating a Dunn’s
multiple comparison post-test for non-parametric data. A P value
of ,0.05 was accepted as significant. Data analysis was performed
using GraphPad Prism 5.0.
Results
LPS-induced release of EVs exacerbates ATP associated
airway inflammation
LPS challenge caused an increase in BALF IL-1b levels,
neutrophils and lung tissue neutrophils. Utilising mice that had
been previously exposed to cigarette smoke, and thus had
increased ATP levels in the BALF, the response to LPS was
significantly exacerbated (Figure 1B–D). This suggests that the
mouse is an appropriate species to model the exacerbation
responses and thus can be used for further investigations into
infection induced release of EVs.
BALF ATP levels were increased in samples from a separate
parallel smoke driven study but not after LPS challenge
(Figure 1A).
Demonstration of the concept that an infective insult can
cause EV release
Before using the in vivo model systems, we initially wanted to use
a cell based system to demonstrate the concept that an infective
insult can cause the release of EVs and that subsequent challenge
of these EVs with ATP will drive the P2X7-dependent release of
IL-1b/IL-18. Treating cultured THP-1 cells with a bacterial
mimetic, LPS, caused an increase in supernatant levels of IL-1b,
IL-18, TNFa and MMP-9 (Figure 2). As expected the levels of
these mediators were not altered by ultracentrifugation, nor were
they altered when the P2X7 inhibitor was added to the cell-free
supernatants (Figure 2). Interestingly, it would appear that
cultured cells release some EVs under ‘‘basal’’ conditions. As
can be seen in Figure 2, ATP triggers some P2X7-dependant IL-1b
release. This could imply that cultured THP-1 cells release EVs
constantly or that it is a consequence of culturing procedures.
Figure 6. Determining if a bacterial mimetic (LPS) can cause the
release of EVs in the lung – Signalling. Mice (n = 6 per group) were
challenged with the aerosolised vehicle of endotoxin-free saline or LPS
(1 mg/ml) in Perspex chambers for 30 minutes. Animals were sacrificed
and BALF obtained 6 hours after challenge. The samples were then
centrifuged (900 g) to remove the white blood cells and then pre-
treated with inhibitors (P2X7 antagonist A 438079 (10
26 M) or caspase-1
inhibitor VX 765 (1027 M)) and incubated for 1 hour. Samples were
then treated with vehicle (PBS) or ATPcS (1023 M), and incubated for a
further 4 hours and subsequent cytokine release was analysed by ELISA.
Data shown as mean +/2 S.E.M. (A: IL-1b, B: TNFa). * = P = 0.0138 (One
way ANOVA followed by a Bonferroni’s Multiple Comparison test).
doi:10.1371/journal.pone.0101087.g006
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Treatment of the cell-free supernatants with ATP increased the
levels of IL-1b and IL-18 but not TNFa and MMP-9 in the EV-
rich (non-ultracentrifuged) LPS challenged samples (Figure 2).
This increase was attenuated when the P2X7 inhibitor, which
suggests this receptor is central to the response. Significantly, when
the samples were ultracentrifuged to remove the EVs, the ATP-
induced increase in IL-1b/IL-18 was lost (Figure 2, right side of
panels). Together this data shows that LPS can cause the release of
EVs which in turn can release IL-1b/IL-18 after ATP stimulation
in a P2X7 receptor dependent manner. Furthermore, importantly
this data suggests that measuring ATP induced IL-1b in cell free
medium is an appropriate surrogate marker of the presence of
viable/functional EVs.
Determining whether infective agents can cause the
release of EVs in the lung
Having demonstrated the concept that an infective insult can
cause the release of EVs in a cell culture system, we then wanted to
determine if this occurred in vivo. To do this we challenged mice
with LPS, collected the lavage fluid and performed EM, Nanosight
assessment and examined ATP-induced IL-1b production. The
inflammatory response after LPS challenge was typical of that
previously described [28,30].
When we prepared the EV fractions from mice challenged with
the bacterial mimetic they appeared to contain more EV-like
structures when compared to the saline challenged controls
(Examples of the imagines are in Figure 3). Furthermore, assessing
the cell-free BALF samples using Nanosight technology showed
that the mice challenged with LPS had more particles around the
size of EVs in their airways (20–1000 nM, Figure 4).
LPS challenging the mice caused an increase in IL-1b, IL-18
and IL-1a in the BALF as expected (Figure 5). Stimulating the cell-
free BALF with ATP resulted in a marked increase in IL-1b and
IL-18, but not IL-1a (Figure 5). Pharmacological assessment of this
increase showed that the ATP induced exacerbation was
dependent on P2X7 and caspase 1 (Figure 6). The levels of
TNFa, a cytokine not thought to be linked to the ATP-P2X7-
Caspase 1 axis, were not altered as expected (Figure 6).
In an attempt to translate our pre-clinical findings, we collected
BALF samples from healthy human subjects challenged with LPS,
removed the white cells and debris and then spiked the BALF with
vehicle or ATP. As can be seen from Figure 7, ATP significantly
increased IL-1b, but not TNFa, in the samples from the subjects
challenged with LPS. Similarly, we measured an increase in IL-18
but not IL-1a after ATP spike in the BALF from LPS challenged
subjects (Figure 7 and data not shown). Like the murine model
samples, we did not detect any change in ATP levels in the human
BALF after LPS challenge (data not shown).
To demonstrate that actual live bacteria could trigger EV
release, we used BALF samples from a H. influenza bacterial
Figure 7. Human translation data: exogenous ATP increases IL-1b/IL-18 level in samples collected from LPS challenged healthy
subjects. Healthy subjects were challenged with inhaled LPS and BALF was collected 6 hours later. The supernatants were then spiked with vehicle
or ATP (1023 M) and incubated for 4 hours; cytokine release was analysed by ELISA. Panel A shows the paired IL-1b data. Panel B, C and D represents
the levels of IL-1b, IL-18 and TNFa, respectively. Data shown as mean +/2 S.E.M. Statistical analysis using a paired T-test.
doi:10.1371/journal.pone.0101087.g007
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challenge model. The inflammatory response observed in the
model was typical of that reported previously [36]. As can be seen
from Figure 8 (left panels) ATP spiking the samples increased the
levels of IL-1b, and not TNFa, suggesting there appears to be
functional EVs present in the airways of bacterially infected
animals.
Similarly, in a model that uses a viral mimetic, poly I:C, which
resulted in a typical inflammatory response [35], ATP spiking
increased levels of IL-1b (Figure 8, right panels). Thus we are
confident that bacterial and viral infections cause the release of
EVs into the airway, and if there are high levels of ATP present in
the airway (like in asthma and COPD), it could trigger the release
of IL-1b and IL-18.
Determining whether the ATP/P2X7 axis is central to the
exacerbation response in vivo
Finally, an experiment was performed to determine if ATP
could trigger P2X7 dependent exacerbation of LPS induced
airway inflammation in vivo. Mice were challenged with LPS +/2
ATP in the presence and absence of a P2X7 inhibitor. LPS
challenge caused an increase in BALF IL-1b and neutrophilia; this
was exacerbated in the mice that received ATP (Figure 9). Whilst
the P2X7 inhibitor, A438079, had no effect on neutrophil numbers
after just LPS challenge (as shown before [28], the ATP
exacerbated response was attenuated by the inhibitor (Figure 9).
Discussion
Exacerbations of both asthma and COPD can be fatal and
represent a growing concern to patients and healthcare providers
[6,8]. These episodes are usually associated with viral and bacterial
infections which enhance the existing inflammatory status, and in
turn compromise lung function [9,11]. We propose that these
exacerbations could be caused by the increased levels of ATP in
the lungs of these patients. Increased levels of ATP could activate
the P2X7/caspase 1 axis in EVs resulting in the release of IL-1b/
IL-18, and subsequent increase in inflammatory and disease status.
To investigate this, we wanted to demonstrate that infective
mimetics/agents could cause the release of EVs in the airway and
that these EVs are functional/viable i.e. they can be triggered into
releasing IL-1b and IL-18 in response to ATP.
It had been previously shown that exposure to smoke increases
ATP levels in the BALF from mice [27] and that co exposure with
smoke and the bacterial mimetic, LPS, led to an enhanced
neutrophilic response which was similar in profile to that in
exacerbating asthma and COPD sufferers [12,13,37,38]. Together
this suggested that the LPS exposure could be causing the release
Figure 8. Determining if live bacteria or a viral mimetic can cause the release of EVs in the lung. Live bacterial model: Mice (n = 6 per
group) were intranasally challenged with Haemophilus influenzae (16107 colony forming units serotype b) in sterile phosphate buffered saline (PBS).
Mice were sacrificed and BALF samples were collected at 6, 24 and 72 hours. The samples were then centrifuged (900 g) to remove the white blood
cells and then treated with vehicle (PBS) or ATPcS (1023 M), incubated for 4 hours and analysed by ELISA. Data shown as mean +/2 S.E.M. (A: IL-1b, B:
TNFa). # =P= 0.0206 (Mann-Whitney). Viral mimetic model: Mice (n = 6 per group) were challenged with vehicle (saline, approximately 25 ml per
nostril) or the viral mimetic Poly I:C (0.6 mg/ml) under inhaled isoflurane. Mice were sacrificed and BALF samples were collected at 2, 6 and 24 hours.
The samples were then centrifuged (900 g) to remove the white blood cells and then treated with vehicle (PBS) or ATPcS (1023 M), incubated for
4 hours and analysed by ELISA. Data shown as mean +/2 S.E.M. (C: IL-1b, D: TNFa).
doi:10.1371/journal.pone.0101087.g008
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of EVs and the smoke-induced ATP could be causing the
enhanced neutrophilia response via the release of enhanced levels
of IL-1b/IL-18. To investigate this hypothesis we repeated the
experiment using our murine model systems. The data clearly
shows that combination of smoke and LPS leads to an exacerbated
inflammatory response with IL-1b and neutrophilia levels
enhanced. The ability to repeat the published data in a second
species gave us confidence in the observation but more impor-
tantly indicated to us that mice are an appropriate species to use
and enabled us to utilise our murine model systems. Furthermore,
whereas we routinely observe an increase in ATP levels in our
smoke model, as can be seen from Figure 1A we do not measure
an increase in our LPS model. In corroboration, in these models
we only observe an increase in caspase 1 activity (a downstream
marker of ATP activity on the P2X7 receptor) in the smoke model
[28]. The lack of LPS induced increase in ATP levels allows us to
interpret the combination and ATP spiking data more readily.
Before further studying the possibility that respiratory infections
can lead to the release of functional EVs in the airway, we first
wanted to demonstrate the phenomenon in a cell based system.
We found that the supernatant from cells treated with a bacterial
mimetic had measurable levels of IL-1b, IL-18, MMP-9 and
TNFa but only the levels of IL-1b and IL-18 were further
increased in the presence of ATP. Furthermore, data showed that
this enhanced release was P2X7-dependent. The role of EVs in
this exacerbated response was confirmed when we compared
supernatants that were ultracentrifuged, to remove the EVs (EV-
deficient), with non-ultracentrifuged samples (EV-rich). Whereas
the addition of ATP increased IL-1b and IL-18 levels in the EV–
rich samples, we did not see a similar increase in the same samples
when EVs were removed. These findings are similar to that
observed by others which gave us confidence in our assessments
and the use of IL-1b as a marker of the existence of functional/
viable EVs [17,20–23,39,40].
To begin to investigate whether respiratory infections caused
the release of EVs we challenged mice with an inhaled bacterial
mimetic. Assessment of the cell free BALF gave EM images that
suggested an increase in particles after LPS challenge. This finding
was quantified using Nanosight technology which gave a clear
increase in particles in the samples harvested from LPS challenged
mice. The size of these particles appeared to be in the 100–
400 nM range, which is reminiscent of microvesicles, rather than
exosomes [32,33]. However, more detailed studies are required to
establish the EV profile and, importantly, to determine the cellular
source. While imaging data is useful it lacks the information
required of these proof of concept studies i.e. that EVs are
functional/viable, can release cytokines upon ATP stimulation via
a P2X7-caspase 1 axis. To do this we used the bioassay as
described. LPS challenge in mice caused an increase in the BALF
IL-1a, IL-1b, IL-18 and TNFa levels as previously found [28].
The levels of IL-1b and IL-18, but not TNFa and IL-1a, were
further increased when the cell-free BALF was spiked with
exogenous ATP. This increase appeared to be dependent on both
P2X7 and caspase 1 suggesting this axis was integral to the
response. Whilst we do not know the exact mechanism that
triggers the release of IL-1b and IL-18 (and not TNFa); the fact
that it can be modulated by P2X7 and caspase 1 inhibitors suggests
it is not simply through lysis. Together however, this data package
does indicated that EVs are released and they are functional.
Furthermore, using ATP induced IL-1b release was an appropri-
ate surrogate marker for the biological fluid we were studying. By
using this bioassay we were able to show that inhaled LPS can
trigger the release of EVs in humans. This suggests that the data
obtained in our murine model systems is translatable. Thus
additional experiments were performed on other murine airway
infection systems. We were able to show that as well as a bacterial
mimetic a live bacteria challenge (H. influenzae, a gram-negative
bacterium) also caused the release of EVs. Furthermore a viral
mimetic, poly:IC, also triggered a similar response. This suggested
to us that, as hypothesised, respiratory infections, whether it is
bacterial or viral (both associated with exacerbation episodes in
human patients), can trigger the release of EVs into the airway.
And that if the levels of ATP are high, as described in patients with
asthma and COPD, the EVs can release IL-1b and IL-18.
Together this data set strongly suggests that infective agents in the
airways cause the release of EVs and that ATP can drive them to
release of IL-1b in a P2X7/caspase 1– dependent manner.
Finally, to determine whether the ATP/P2X7 axis is central to
the exacerbation seen in vivo, we used a mechanistic model. The
reason was that data in the disease model systems has shown that
modulation of ATP levels or attenuation of P2X7 inhibits the
inflammatory response [27,28,41], making interpretation of the
exacerbation part of the model system difficult. Previously we have
shown that the inflammation in the standard LPS model is not
Figure 9. Determining whether the ATP/P2X7 axis is central to
the exacerbation response in vivo. Mice (n = 8 per group) were
challenged with the aerosolised vehicle of endotoxin-free saline or LPS
(1 mg/ml) in Perspex chambers for 30 minutes. Four hours later the
mice were intranasally dosed with saline (2 ml/kg) or ATPcs (0.001 mg/
kg) whilst under light anaesthesia (4% isoflurane in oxygen). The mice
received oral vehicle or P2X7 inhibitor, A438079, 30 minutes prior to the
ATP challenge, 4 hours after the challenge and 1 hour prior to cull.
Twenty four hours after the LPS exposure the mice were culled and
lavaged. IL-1b (A) and neutrophil (B) numbers were measured in the
BALF. Data shown as mean +/2 S.E.M. An unpaired T-test was used for
the statistical analysis. * = P = 0.0378 (Panel A); * = P = 0.0162 (Panel B).
doi:10.1371/journal.pone.0101087.g009
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modulated by a P2X7 inhibitor [28], making it ideal to use as a
mechanistic model for testing the importance of the P2X7 receptor
in the ATP-driven exacerbation. The data generated clearly show
that exogenous ATP caused a P2X7-dependent exacerbation of
airway neutrophilia. The limitation of this in vivo assessment is that
we can only infer from the in vitro/ex vivo data that the IL-1b
released after ATP challenge is coming from EVs, there are other
cellular sources in the airway like macrophages which we cannot
rule out.
In our systems ATP alone did not cause airway neutrophilia;
this is different to that reported by others [42]. Whilst we do
believe that ATP can be a driving factor in airway inflammation, a
good example is our published data in the smoke model [28], we
think that ATP alone is not sufficient to cause cellular
inflammation, other co-factors such as chemoattractants are
required. Thus we are not surprised when the ATP alone did
not cause neutrophilia, we cannot however explain the data
published by Cicko et al. [42], it could perhaps be due to
experimental design, health status of animals, etc. Another aspect
of our findings that would appear to contradict published data is
the lack of effect of the P2X7 receptor inhibitor on the LPS-only
inflammation. Moncao-Ribeiro et al. published that P2X7 KO
mice were protected from LPS challenge, with all aspects of the
inflammatory response reduced in the GM mice compared to the
wild type controls [43]. We have now repeated this study with
litter matched controls and in agreement with our previous
published findings [28], we find that in our model system the P2X7
receptor is not involved in the inflammation (data not shown). To
us this result makes sense as it is what one would expect given
there is no increase in ATP or the downstream marker, caspase 1
activity, in our model and it is well know that the LPS response
triggers NF-kB driven inflammation. Again we cannot explain the
difference in data but suggest it could perhaps be due to
experimental design.
In summary, the results of this study indicate that respiratory
infections, bacterial and viral, can trigger the release of functional
EVs in mice and man. Furthermore, upon ATP activation, the
EVs released IL-1b and IL-18 in a P2X7/caspase-1 axis
dependent manner resulting in exacerbated neutrophilia. We
suggest EVs and this signalling pathway could prove to be a viable
therapeutic target in the future to improve the clinical outcomes of
the exacerbations of asthma and COPD.
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